מן הרשת 28.03.202411:51 A novel model to predict recurrence-free survival and melanoma-specific survival Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis The Lancet Oncology
מן הרשת 28.03.202411:49 First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma In an event more than three decades in the making, the Food and Drug Administration (FDA) has approved lifileucel (Amtagvi), the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs National Cancer Institue
מן הרשת 28.03.202411:48 Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma Is there an association between smoking and outcomes of patients with clinically node-negative cutaneous melanoma? JAMA Netw Open.
מן הרשת 15.02.202414:33 PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy Checkpoint inhibition (CPI), particularly that targeting the inhibitory coreceptor programmed cell death protein 1 (PD-1), has transformed oncology Nature Cancer
מן הרשת 15.02.202414:32 Predicting Treatment Response in Patients with Advanced Melanoma FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma Clin Cancer Res
מן הרשת 15.02.202414:29 The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma hese findings identify the CoREST repressor complex as a central mediator of melanoma phenotype plasticity and resistance to targeted therapy and suggest that CoREST inhibitors may prove beneficial to patients with BRAFi-resistant melanoma J Clin Invest
מן הרשת 15.02.202414:28 סמפילימאב עבור מושתלי כליה עם קרצינומה עורית מתקדמת של תאי קשקש Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Journal of Clinical Oncology
מן הרשת 15.02.202414:27 חיזוי הישרדות ללא הישנות והישרדות כוללת עבור חולים עם מלנומה בשלב II: מחשבון MIA Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator Journal of Clinical Oncology
מן הרשת 28.01.202411:16 Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusion-positive cancers, including those with resistance mutations such as ROS1 G2032R New England Journal of Medicine
מן הרשת 28.01.202410:52 Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial Lancet
מן הרשת 14.01.202411:49 Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial Journal of Clinical Oncology
מן הרשת 09.01.202412:00 Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis What are the clinical and histopathologic features of dupilumab-associated lymphoid reactions in patients with atopic dermatitis? JAMA Dermatol
מן הרשת 07.01.202411:30 Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression Ann Clin Transl Neurol
מן הרשת 07.01.202411:28 Expert opinion on the long-term use of cladribine tablets for multiple sclerosis Systematic literature review of real-world evidence Mult Scler
מן הרשת 07.01.202411:27 Emerging therapies to target CNS pathophysiology in multiple sclerosis The rapidly evolving therapeutic landscape of multiple sclerosis (MS) has contributed to paradigm shifts in our understanding of the biological mechanisms that contribute to CNS injury and in treatment philosophies Nature Reviews Neurology
תגובות אחרונות